Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a decades-old arthritis drug protect dialysis patients' hearts and veins?

NCT ID NCT07762807

Disease control Sponsor: King's College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tests whether low-dose colchicine, an inexpensive anti-inflammatory drug, is safe and acceptable for people on hemodialysis. Researchers will give 100 dialysis patients colchicine for about 3 months, monitoring side effects and how many stick with it. The goal is to see if a larger trial is possible to test whether colchicine can reduce heart attacks and strokes and help dialysis access points last longer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
colchicine 0.5 mg taken orally once daily for 3 months and 2 weeks
What this could lead to
If tolerated, colchicine could reduce heart attacks and strokes in dialysis patients and help their vascular access last longer, potentially improving survival and quality of life.
What could go wrong
This is a small feasibility study, not a large efficacy trial. Dialysis patients may not tolerate colchicine well, and any benefits remain unproven until larger trials are done.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Anyone who is undergoing haemodialysis. 2. Aged 18 or over 3. Able to give informed consent Exclusion Criteria: 1. Already taking colchicine for a clinical indication. 2. Taking a drug known to increase colchicine levels. 3. Has a previously documented intolerance of or allergy to colchicine 4. Has a history of chronic liver disease, or abnormal liver function (i.e. ALT \> 1.5 x upper limit of normal). Patients with a history of hepatitis are eligible provided these limits are not exceeded.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colchicine are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colchicine poisoning end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colchicine Feasibility study Haemodialysis patients

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Guy's and St Thomas' NHS Trust

    RECRUITING

    London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.